A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
This study has been completed.
First Posted: January 16, 2013
Last Update Posted: November 11, 2016
Information provided by (Responsible Party):